StreetInsider.com News Articles

Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

Wed, 07 Oct 2026 01:59:00 -0400

Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end

ZUG, Switzerland, October 7, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced that Riad Sherif, M.D., Chief Executive Officer of Oculis, will present at Eyecelerator @ AAO 2026 on October 8, 2026, and that the Company will sponsor the Neuro-Ophthalmology Subspecialty Day at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

Wed, 07 Oct 2026 01:59:00 -0400

Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Thu, 01 Oct 2026 02:00:00 -0400

Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life

ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, is partnering with the National Multiple Sclerosis Society on its Campaign to End MS, as the industry partner focusing on Vision, officially launching today, on October 1, 2026. This 5-year campaign aims to accelerate research breakthroughs, improve access to care, and create

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Thu, 01 Oct 2026 02:00:00 -0400

Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Thu, 01 Oct 2026 02:00:00 -0400

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Thu, 01 Oct 2026 02:00:00 -0400

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life

Form 6-K Oculis Holding AG For: Sep 30

Wed, 30 Sep 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260930/27129360.html

Lionel Carnot resigns from Oculis board after nearly a decade

Wed, 30 Sep 2026 16:47:44 -0400

Oculis Holding AG (Nasdaq: OCS) announced that board member Lionel Carnot has resigned from its Board of Directors, effective September 30, 2026, after serving since 2017.

According to the company's statement, Carnot's departure is a personal decision and is not related to any disagreement with the company over its operations, policies, or practices.

Carnot said in a statement: "As the Company enters its next stage of growth, this is a timely point for me to step down and focus on other commitments. As an investor, I remain confident in the potential of Oculis' pipeline and look forward to the Company achieving important

Lionel Carnot resigns from Oculis board after nearly a decade

Wed, 30 Sep 2026 16:47:44 -0400

Oculis Holding AG (Nasdaq: OCS) announced that board member Lionel Carnot has resigned from its Board of Directors, effective September 30, 2026, after serving since 2017.

According to the company's statement, Carnot's departure is a personal decision and is not related to any disagreement with the company over its operations, policies, or practices.

Oculis Announces Resignation of Lionel Carnot from Board of Directors

Wed, 30 Sep 2026 16:46:40 -0400

ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announces that director Lionel Carnot will be resigning from the Board of Directors, effective today, after nearly a decade of dedicated service since 2017.

Anthony Rosenberg, Chair of the Board, remarked: “On behalf of the Board and the entire Oculis team, we wish to extend our sincere gratitude to Lionel for his invaluable service, leadership and guidance over nearly a

Oculis Announces Resignation of Lionel Carnot from Board of Directors

Wed, 30 Sep 2026 16:46:40 -0400

Oculis Holding AG (OCS) Reiterated at Buy by Stifel as Privosegtor Becomes Core Focus

Mon, 28 Sep 2026 07:33:14 -0400

Stifel analyst Annabel Samimy reiterated a Buy rating and $40.00 price target on Oculis Holding AG (NASDAQ: OCS).

The analyst commented, "We reiterate our Buy on OCS, $40 TP. We hosted management on the road as privosegtor’s pivotal development in neuro-ophthalmology begins in earnest. Privosegtor has become the core focus for its strong, evidence-based potential in neuroprotection, with first pivotal PIONEER-1 in lead indication of AON now enrolling. PIONEER-2 (AON) and PIONEER-3 (NAION) beginning 4Q26, with a possible full MS relapse label achievable via PIONEER-4 in ambulatory relapse. Collectively, the three indications have >$20bn TAM. Separately, licaminlimab’s Ph.2/3 PREDICT-1 readout is

Oculis Holding AG (OCS) PT Raised to $39 at H.C. Wainwright

Fri, 18 Sep 2026 06:48:52 -0400

(Updated - September 18, 2026 6:48 AM EDT)

H.C. Wainwright analyst Yi Chen raised the price target on Oculis Holding AG (NASDAQ: OCS) to $39.00 (from $26.00) while maintaining a Buy rating.

The analyst commented: "The PREDICT-1 trial of licaminlimab in dry eye disease (DED) is actively enrolling patients. The enrollment target is approximately 160 patients, with approximately 2/3 having the specified TNFR1 genotype. The primary endpoint is the change from baseline to Day 29 in the global ocular discomfort severity score in patients with the specified TNFR1 genotype. The same outcome measure is also evaluated in the overall study population as

Oculis Holding AG (OCS) PT Raised to $39 at H.C. Wainwright

Fri, 18 Sep 2026 06:48:52 -0400

(Updated - September 18, 2026 6:48 AM EDT)

H.C. Wainwright analyst Yi Chen raised the price target on Oculis Holding AG (NASDAQ: OCS) to $39.00 (from $26.00) while maintaining a Buy rating.

H.C. Wainwright Reiterates Buy Rating on Oculis Holding AG (OCS)

Tue, 25 Aug 2026 06:59:10 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $26.00 price target on Oculis Holding AG (NASDAQ: OCS).

The analyst commented: "This morning, Oculis announced that the first patient has been treated in the PIONEER-1 registrational trial of privosegtor for the treatment of optic neuritis (ON). As a novel peptoid small molecule that can cross the blood-brain and retinal barriers, privosegtor is being developed to be the first neuroprotective therapy for ON. The PIONEER program has two registrational trials. PIONEER-1 (n=210) is evaluating privosegtor in acute-onset ON across a broad population, including patients with and without multiple sclerosis (MS). In

Oculis Holding AG (OCS) PT Lowered to $20 at JPMorgan

Fri, 14 Aug 2026 09:11:14 -0400

JPMorgan analyst Tessa Romero lowered the price target on Oculis Holding AG (NASDAQ: OCS) to $20.00 (from $23.00) while maintaining a Overweight rating.

Oculis Holding AG (OCS) Reiterated at Buy by Stifel After CEO Chat

Fri, 14 Aug 2026 08:19:12 -0400

Stifel analyst Annabel Samimy reiterated a Buy rating and $40.00 price target on Oculis Holding AG (NASDAQ: OCS).

The analyst commented, "At our Biotech Summer Summit, we sat with CEO Riad Sherif primarily to discuss lead asset privosegtor, which is entering multiple pivotal-stage trials in neuro-ophthalmology starting with acute optic neuritis/AON. Site activation takes time in these event-driven indications given the multidisciplinary management, but actual treatment with privosegtor is straightforward. The AON similarities have given FDA confidence to rapidly move privosegtor into MS relapse, which would substantially increase privosegtor’s addressable population (~170k patients vs. ~35k each for AON/NAION)—the initial anticipated label

Form 6-K Oculis Holding AG For: Aug 10

Mon, 10 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260810/26894668.html

Form 6-K Oculis Holding AG For: Aug 10

Mon, 10 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260810/26894668.html

Form S-8 Oculis Holding AG

Thu, 06 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260806/26885067.html

Form S-8 Oculis Holding AG

Thu, 06 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260806/26885067.html

Form 6-K Oculis Holding AG For: Jun 30

Thu, 06 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260806/26884259.html

Form 6-K Oculis Holding AG For: Jun 30

Thu, 06 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260806/26884259.html

Form 6-K Oculis Holding AG For: Jun 25

Thu, 25 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260625/26692202.html

Form 6-K Oculis Holding AG For: Jun 25

Thu, 25 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260625/26692202.html